Targeting GLP-1 receptor trafficking to improve agonist efficacy.
Jones B, Buenaventura T, Kanda N, Chabosseau P, Owen BM, Scott R, Goldin R, Angkathunyakul N, Corrêa IR Jr, Bosco D, Johnson PR, Piemonti L, Marchetti P, Shapiro AMJ, Cochran BJ, Hanyaloglu AC, Inoue A, Tan T, Rutter GA, Tomas A, Bloom SR.
Jones B, et al. Among authors: bosco d.
Nat Commun. 2018 Apr 23;9(1):1602. doi: 10.1038/s41467-018-03941-2.
Nat Commun. 2018.
PMID: 29686402
Free PMC article.
Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term insulin release, which is dependent on a reduction in beta-arrestin recruitment and faster agonist dissociation rates. ...
Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term ins …